2021
Continuous Glucose Monitoring for the Internist
Lee GS, Lupsa BC. Continuous Glucose Monitoring for the Internist. Medical Clinics Of North America 2021, 105: 967-982. PMID: 34688421, DOI: 10.1016/j.mcna.2021.06.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringContinuous glucose monitoring systemDiabetes mellitusGlucose monitoring systemGlucose monitoringGlycemic patternsType 2 diabetes mellitusType 1 diabetes mellitusTreatment regimenDiabetes careGlucose readingsHemoglobin AGlucose dataMellitusPatientsInterstitial fluidConvenient wearable devices
2018
Diabetes medications and cardiovascular disease
Lupsa BC, Inzucchi SE. Diabetes medications and cardiovascular disease. Current Opinion In Endocrinology Diabetes And Obesity 2018, 25: 87-93. PMID: 29369916, DOI: 10.1097/med.0000000000000400.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitus patientsPeptide-1 receptor agonistsGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetes mellitus patientsType 2 diabetesCause of mortalityCardiovascular complicationsCardiovascular outcomesDiabetes medicationsMicrovascular complicationsCardiovascular effectsMellitus patientsReceptor agonistDrug categoriesIntensive controlDiseaseComplicationsMedicationsClear benefitRecent studiesSignificant improvement
2010
Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies
Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P. Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: 3641-3647. PMID: 20484479, PMCID: PMC2913034, DOI: 10.1210/jc.2010-0167.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAutoantibodiesBlood GlucoseCyclophosphamideDrug Therapy, CombinationFemaleHumansHyperandrogenismHyperglycemiaImmunosuppressive AgentsInsulin ResistanceMaleMiddle AgedReceptor, InsulinRituximabTreatment OutcomeConceptsType B insulin resistanceInsulin resistanceAmelioration of hyperglycemiaPathogenic autoantibody productionSerious adverse eventsRare autoimmune disorderInitiation of treatmentForm of immunosuppressionInsulin receptor autoantibodiesSevere acanthosis nigricansAdverse eventsInsulin therapyMedication regimenPulse corticosteroidsInsulin doseReceptor autoantibodiesAutoantibody productionAcanthosis nigricansAutoimmune disordersGlycated hemoglobinStandardized treatmentTreatment protocolEndocrine parametersPatientsSteroids results